Lynx1 Capital Management LP
About Lynx1 Capital Management LP’s 13F portfolio
Lynx1 Capital Management LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Lynx1 Capital Management LP reported $865.5M across 27 US-listed positions (). Its largest position is GH RESEARCH PLC (GHRS) at 41% of the reported book, and its ten biggest holdings make up 99% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: GHRS GH RESEARCH PLC | $18.56 +1.70% | 41% | 13.3M | $356.5M |
| 2 | NASDAQ: CGEM CULLINAN THERAPEUTICS INC | $9.07 +0.67% | 19% | 9.0M | $163.2M |
| 3 | NASDAQ: STOK STOKE THERAPEUTICS INC | $26.93 +0.90% | 15% | 4.0M | $132.1M |
| 4 | NASDAQ: AGIO AGIOS PHARMACEUTICALS INC | $28.76 −3.10% | 15% | 3.4M | $126.5M |
| 5 | NASDAQ: CCCC C4 THERAPEUTICS INC | $2.44 −1.41% | 4.0% | 7.3M | $34.2M |
| 6 | NASDAQ: KRRO KORRO BIO INC | $12.19 −2.01% | 2.3% | 1.5M | $20.3M |
| 7 | NASDAQ: TCRX TSCAN THERAPEUTICS INC | $0.14 −3.84% | 0.9% | 8.0M | $7.9M |
| 8 | NASDAQ: DTIL PRECISION BIOSCIENCES INC | $6.91 −2.68% | 0.9% | 950K | $7.5M |
| 9 | NASDAQ: NEUP NEUPHORIA THERAPEUTICS INC | $2.32 +1.75% | 0.4% | 875K | $3.8M |
| 10 | NASDAQ: PASG PASSAGE BIO INC | $3.61 −12.70% | 0.4% | 674K | $3.3M |
| 11 | NASDAQ: CGON CG ONCOLOGY INC | $81.90 +2.38% | 0.3% | 31K | $2.2M |
| 12 | NASDAQ: PLRX PLIANT THERAPEUTICS INC | $0.62 −6.20% | 0.2% | 1.8M | $2.0M |
| 13 | NASDAQ: TRDA ENTRADA THERAPEUTICS INC | $4.64 −7.75% | 0.2% | 179K | $1.3M |
| 14 | NASDAQ: VYNE VYNE THERAPEUTICS INC | $30.45 +8.56% | 0.1% | 1.6M | $1.1M |
| 15 | NASDAQ: PRQR PROQR THRAPEUTICS N V | $1.05 −4.55% | 0.1% | 521K | $970K |
| 16 | NASDAQ: TRAW TRAWS PHARMA INC | $0.23 −5.15% | 0.1% | 559K | $472K |
| 17 | NASDAQ: FHTX FOGHORN THERAPEUTICS INC | $1.78 −0.56% | 0.0% | 62K | $301K |
| 18 | NASDAQ: DNLI DENALI THERAPEUTICS INC | $18.20 −1.09% | 0.0% | 12K | $300K |
| 19 | NASDAQ: XNCR XENCOR INC | $34.01 −1.10% | 0.0% | 18K | $293K |
| 20 | NASDAQ: ABSI ABSCI CORPORATION | $8.16 −0.24% | 0.0% | 21K | $246K |
| 21 | NASDAQ: HOWL WEREWOLF THERAPEUTICS INC | $0.99 −4.30% | 0.0% | 658K | $237K |
| 22 | NASDAQ: IMTX IMMATICS N.V | $5.95 −2.46% | 0.0% | 23K | $235K |
| 23 | NASDAQ: AVTX AVALO THERAPEUTICS INC | $6.75 +0.75% | 0.0% | 10K | $187K |
| 24 | NASDAQ: BOLT BOLT BIOTHERAPEUTICS INC | $5.06 −0.78% | 0.0% | 31K | $119K |
| 25 | NYSE: NUVB NUVATION BIO INC | $3.81 +0.79% | 0.0% | 16K | $91K |
Showing 1–25 of 27 positions on this page reported in this 13F.
- Healthcare100%
- AddedGHRSGH RESEARCH PLC+23.2%$356.5M
- AddedAGIOAGIOS PHARMACEUTICALS INC+30.5%$126.5M
- AddedCCCCC4 THERAPEUTICS INC+4.7%$34.2M
- AddedPASGPASSAGE BIO INC+8.0%$3.3M
- NewPLRXPLIANT THERAPEUTICS INC—$2.0M
- AddedPRQRPROQR THRAPEUTICS N V+661%$970K
- AddedTRAWTRAWS PHARMA INC+3611%$472K
- NewFHTXFOGHORN THERAPEUTICS INC—$301K
- NewAVTXAVALO THERAPEUTICS INC—$187K
- NewNUVBNUVATION BIO INC—$91K
- ReducedSTOKSTOKE THERAPEUTICS INC−15.2%$132.1M
- ReducedDTILPRECISION BIOSCIENCES INC−3.5%$7.5M
- ReducedCGONCG ONCOLOGY INC−0.6%$2.2M
- ReducedTRDAENTRADA THERAPEUTICS INC−15.6%$1.3M
- ReducedDNLIDENALI THERAPEUTICS INC−99.4%$300K
- ReducedXNCRXENCOR INC−96.6%$293K
- ReducedIMTXIMMATICS N.V−89.3%$235K
- SoldIBIOIBIO INC−100%—
- SoldDSGNDESIGN THERAPEUTICS INC−100%—
Reading Lynx1 Capital Management LP’s 13F portfolio
Lynx1 Capital Management LP’s $865.5M 13F book is spread across 27 reported positions and is highly concentrated — its ten largest positions alone are 99% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are GHRS, CGEM, STOK, AGIO and CCCC, led by GH RESEARCH PLC (GHRS) at 41% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What Lynx1 Capital Management LP changed last quarter
Between 2026-03-31 and Q2 2026, Lynx1 Capital Management LP was a net buyer: it opened 6 new positions and added to 6 more, while trimming 7 and closing 2 outright. Against a 27-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was GH RESEARCH PLC (GHRS), and its biggest reduction was STOKE THERAPEUTICS INC (STOK).
What a 13F does and doesn’t reveal
A 13F captures only Lynx1 Capital Management LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Lynx1 Capital Management LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Lynx1 Capital Management LP's profile on this page is built directly from those filings.
How current is the 13F data on Lynx1 Capital Management LP's page?
It reflects Lynx1 Capital Management LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Lynx1 Capital Management LP files its next quarterly report, this page refreshes automatically.
Can I see Lynx1 Capital Management LP's complete list of holdings?
This page highlights Lynx1 Capital Management LP's largest positions rather than all 27 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Lynx1 Capital Management LP's filings.
Does a 13F show everything Lynx1 Capital Management LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Lynx1 Capital Management LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Lynx1 Capital Management LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

